ReviewToxins2020
Inflammation and Premature Ageing in Chronic Kidney Disease.
Review in Toxins, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 142 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
142 citing papers in PubMed, 2 syntheses or guidelines pooled it, 226 citations in OpenAlex.
- Comparative efficacy of different interventions on circulating factors in sarcopenia individuals: a systematic review and network meta-analysis.Aging clinical and experimental research · 2026Pooled it
- A systematic review and meta-analysis demonstrating Klotho as an emerging exerkine.Scientific reports · 2022Pooled it
- TA-TMA and GVHD are distinct consequences of endothelial injury: a MIDAS consortium study.Blood advances · 2026Article
- Cellular senescence in kidney diseases: a bibliometric analysis of global trends, knowledge bases, and emerging therapeutic frontiers.International urology and nephrology · 2026Article
- The associations between cardiometabolic index and mortalities in chronic kidney disease.Medicine · 2026Article
- A Critical Reassessment of Inflammatory and Nutritional Indices (PNI, GNRI, SII, NLR, PLR) for Predicting Arteriovenous Fistula Maturation and Long-Term Patency: A 945-Patient Cohort.Journal of clinical medicine · 2026Article
- Association of E-Selectin with Inflammation, Mineral and Bone Disorder, and Endothelial Dysfunction in Hemodialysis Patients.International journal of molecular sciences · 2026Article
- VSIG4 Expression During Renal Aging Is Accelerated by Type 2 Diabetes in Mice.Life (Basel, Switzerland) · 2026Article
- Review
- Association between triglyceride-to-high-density lipoprotein cholesterol ratio and albuminuria in patients with type 2 diabetes: a cross-sectional study.Frontiers in nutrition · 2026Article
- Association of the platelet-to-albumin ratio with diabetic nephropathy lesions via a fine-tuning-free large language model framework.Frontiers in medicine · 2026Article
- Neutrophil Extracellular Traps in Heart Failure: From Pathophysiological Mechanisms to Therapeutic Targets.Journal of inflammation research · 2026Review
- Article
- Inverse association of circulating kallikrein-related peptidase 7 with renal function and mortality risk in patients with chronic kidney disease.Frontiers in endocrinology · 2026Article
- Preclinical approaches to studying liver and kidney fibrosis: models and methodologies.Frontiers in pharmacology · 2026Review
- Circulating microRNAs miR-21-5p, miR-23a-3p and miR-26a-5p reflect clinical and molecular features of aging.Scientific reports · 2025Article
- Is it true that lower PTH control is associated with lower levels of inflammatory cytokines in patients with chronic kidney disease?Annals of medicine · 2025Article
- Immunological phenotype in asthma and its impact on long-term renal outcomes.Scientific reports · 2025Article
- Stress Pathways in Chronic Kidney Disease: Linking Cortisol, Oxidative Stress, and Inflammation.Antioxidants (Basel, Switzerland) · 2025Review
- DNA Damage and Bisphenol Levels in Chronic Kidney Disease Patients Undergoing Hemodialysis.Journal of xenobiotics · 2025Article
82 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
Persistent low-grade inflammation and premature ageing are hallmarks of the uremic phenotype and contribute to impaired health status, reduced quality of life, and premature mortality in chronic kidney disease (CKD). Because there is a huge global burden of disease due to CKD, treatment strategies targeting inflammation and premature ageing in CKD are of particular interest. Several distinct features of the uremic phenotype may represent potential treatment options to attenuate the risk of progression and poor outcome in CKD. The nuclear factor erythroid 2-related factor 2 (NRF2)-kelch-like erythroid cell-derived protein with CNC homology [ECH]-associated protein 1 (KEAP1) signaling pathway, the endocrine phosphate-fibroblast growth factor-23-klotho axis, increased cellular senescence, and impaired mitochondrial biogenesis are currently the most promising candidates, and different pharmaceutical compounds are already under evaluation. If studies in humans show beneficial effects, carefully phenotyped patients with CKD can benefit from them.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.